World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 12 December 2020
Main ID:  NCT02820493
Date of registration: 17/05/2016
Prospective Registration: Yes
Primary sponsor: Universita degli Studi di Genova
Public title: Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
Scientific title: Effectiveness of Vedolizumab Therapy in Inducing Clinical Remission in CD Patients Naïve to Anti-TNF and Its Capability to Halt Disease Progression
Date of first enrolment: September 2016
Target sample size: 0
Recruitment status: Withdrawn
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 4
Countries of recruitment
Key inclusion & exclusion criteria

Inclusion Criteria:

- Have given written informed consent to participate

- Be aged between 18 and 80

- Have a moderate/severe CD defined by an HBI >7 CD

Exclusion Criteria:

- previous treatment with anti-TNF drugs,

- concomitant use of immune-modulator drugs for CD (azathioprine/6-mercaptopurine,

- ulcerative colitis (UC) or inflammatory bowel disease undetermined (IBD-U) diagnosis

- symptomatic obstructive disease

- bowel resection within the past 6 months

- ileostomy

- extensive small bowel resection (as determined by the investigator) or a short bowel

- patients who are currently receiving total parenteral nutrition

- history of cancer in the past 5 years

- pregnancy known at the study inclusion

- positive Clostridium difficile stool assay

- Listeria, human immunodeficiency virus, central nervous system demyelinating disease,
untreated tuberculosis

Age minimum: 18 Years
Age maximum: 80 Years
Gender: All
Health Condition(s) or Problem(s) studied
Crohn Disease
Drug: vedolizumab
Primary Outcome(s)
Harvey Bradshaw index [Time Frame: Week 0-14]
Secondary Outcome(s)
anti-drug antibodies [Time Frame: Week 0-2-6-14-22-30-38-46-54]
fecal VDZ loss [Time Frame: Week 0-2-6-14-22-30-38-46-54]
Lèmann Index [Time Frame: Week 0 and Week 54]
VDZ trough levels [Time Frame: Week 0-2-6-14-22-30-38-46-54]
Secondary ID(s)
EVeA Study
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history